MolPort-001-798-473

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

Will data integrity concerns on clinical trials done at GVK Biosciences go beyond Europe?

 Over 700 commonly used generic medicines were recommended for suspension by the European Medic